Mr. Stephen Van Deventer reports

PREVECEUTICAL PROVIDES CLARIFICATION OF NEWS RELEASE ANNOUNCING UPDATE ON PLAN OF ARRANGEMENT WITH BIOGENE THERAPEUTICS INC.

Further to the news release of earlier today, Preveceutical Medical Inc. has clarified that shareholders of record of Nov. 24, 2025, will be issued new common shares of Preveceutical and 0.02 of one share of BioGene Therapeutics Inc.

About Preveceutical Medical Inc.

Preveceutical is a health science company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. Preveceutical aims to be a leader in preventive health sciences, and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel program; nature identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

We seek Safe Harbor.